US residents only

FInd out more about our patient support programs

Help verify your insurance coverage for OSENVELT, determine your plan-specific requirements, and understand your available benefits.

ENROLL FOR SUPPORT

Got a prescription? Check your eligibility for the Celltrion CARES® Co-pay Program.

If eligible, you may pay as little as $0* out of pocket for each dose.

*Only for commercially insured patients. Eligibility criteria and program maximums apply. Please see full Terms and Conditions.

VISIT CELLTRION CARES

Enroll in Celltrion CONNECT or call 1‑877‑81CONNC
(1‑877‑812‑6662), Monday – Friday between 8 AM – 8 PM ET.

Resources for you

To support you on OSENVELT, we have developed this comprehensive brochure, available below.

OSENVELT Brochure

Answers to questions you may have about starting treatment with OSENVELT.

Download

IMPORTANT SAFETY INFORMATION

If you receive OSENVELT, you should not receive other denosumab products at the same time.

OSENVELT can cause serious side effects including:

Serious allergic reactions. Serious allergic reactions have occurred with denosumab products. Call your doctor or seek emergency care immediately if you experience symptoms such as low blood pressure (hypotension), rash, difficulty breathing, itching, throat tightness, hives, or swelling of your face, lips, or tongue.

Low blood calcium (Hypocalcemia). OSENVELT can lower your blood calcium levels, which can become severe or even life-threatening. Your doctor will check your calcium levels before and during treatment, especially in the first few weeks. You may need to take calcium, magnesium, and vitamin D supplements as instructed by your doctor. Your risk may be higher if you have kidney problems or take other medicines that lower blood calcium. Call your doctor immediately if you experience symptoms of low blood calcium, such as muscle spasms or cramps, numbness or tingling in fingers, toes, or around your mouth, twitching or stiffness.

Severe jawbone problems (osteonecrosis). Severe jaw bone problems may happen when you take OSENVELT. Your doctor should examine your mouth before starting treatment and may advise seeing a dentist. Practice good oral care and consult your doctor or dentist if needed.

Unusual thigh bone fractures. Symptoms include new or unusual pain in your hip, groin, or thigh.

High Blood Calcium After Stopping Treatment. If you have giant cell tumor of bone or are still growing, stopping OSENVELT can lead to high calcium levels in your blood (hypercalcemia). This condition can become severe, require hospitalization, and affect your kidneys. Your doctor will monitor your calcium levels after stopping treatment. Call your doctor right away if you notice symptoms of high blood calcium, such as nausea or vomiting, increased thirst or urination, confusion or tiredness, muscle weakness or pain. Follow your doctor's instructions carefully, and keep all scheduled appointments for calcium monitoring.

Multiple Spine Fractures After Stopping OSENVELT. After stopping treatment with OSENVELT, some patients have experienced multiple spine fractures. Your risk is higher if you have osteoporosis, previous fractures, or other risk factors. Your doctor will assess your individual fracture risk when stopping OSENVELT.

Risk to Unborn Babies. OSENVELT may harm your unborn baby if you take it while pregnant or within 5 months before becoming pregnant. Animal studies have shown serious harm, including pregnancy loss, birth defects, abnormal bone growth, missing lymph nodes, and slow growth after birth. Your doctor will check if you are pregnant before starting OSENVELT. Tell your doctor immediately if you become pregnant or think you may be pregnant during treatment.

Do not take OSENVELT if you have low blood calcium, are pregnant or planning pregnancy, or if you're allergic to denosumab or any ingredients in OSENVELT.

Before taking OSENVELT, tell your doctor if you:

  • take other denosumab products
  • have low blood calcium
  • cannot take daily calcium and vitamin D supplements
  • take medicines that can lower blood calcium
  • plan dental surgery or tooth removal
  • are pregnant, planning pregnancy, or breastfeeding. OSENVELT may harm an unborn baby; a pregnancy test is required before treatment; use effective birth control during treatment and for 5 months after your last dose; inform your doctor immediately if pregnancy occurs. It is unknown if OSENVELT passes into breast milk; do not breastfeed during treatment.

Tell your doctor of all medicines, vitamins, and herbal supplements you take. Keep an updated list to share with healthcare providers.

The most common side effects of OSENVELT are:

For patients with Bone Metastasis from Solid Tumors: fatigue or weakness, low phosphate levels, and nausea.

For patients with Multiple Myeloma: diarrhea, low phosphate, nausea, fatigue, low calcium, shortness of breath, and anemia.

For patients with Giant Cell Tumor of Bone: joint pain, headache, nausea, back pain, fatigue, and pain in arms or legs.

For patients with Hypercalcemia of Malignancy: nausea, trouble breathing, decreased appetite, and headache.

Tell your doctor if side effects are bothersome or persistent. These are not all possible side effects. Call your doctor for advice on side effects or report them to the FDA at 1‑800‑FDA‑1088.

Please see full Prescribing Information and talk with your healthcare provider.

INDICATIONS

OSENVELT (denosumab-bmwo) is a prescription medicine used to:

  • Help prevent bone complications in patients with multiple myeloma and in patients whose cancer from solid tumors has spread to the bones.
  • Treat adults and adolescents (whose bones have stopped growing) with giant cell tumor of bone that cannot be removed with surgery, or when surgery could cause severe complications.
  • Treat high blood calcium caused by cancer (hypercalcemia of malignancy) that has not improved after treatment with bisphosphonates.

Please see full Prescribing Information and talk with your healthcare provider.

INDICATIONS

OSENVELT® (denosumab-bmwo) is a RANK ligand (RANKL) inhibitor indicated for:

  • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
  • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
  • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

IMPORTANT SAFETY INFORMATION

If you receive OSENVELT, you should not receive other denosumab products at the same time.

OSENVELT can cause serious side effects including:

Serious allergic reactions. Serious allergic reactions have occurred with denosumab products. Call your doctor or seek emergency care immediately if you experience symptoms such as low blood pressure (hypotension), rash, difficulty breathing, itching, throat tightness, hives, or swelling of your face, lips, or tongue.

Low blood calcium (Hypocalcemia). OSENVELT can lower your blood calcium levels, which can become severe or even life-threatening. Your doctor will check your calcium levels before and during treatment, especially in the first few weeks. You may need to take calcium, magnesium, and vitamin D supplements as instructed by your doctor. Your risk may be higher if you have kidney problems or take other medicines that lower blood calcium. Call your doctor immediately if you experience symptoms of low blood calcium, such as muscle spasms or cramps, numbness or tingling in fingers, toes, or around your mouth, twitching or stiffness.

Severe jawbone problems (osteonecrosis). Severe jaw bone problems may happen when you take OSENVELT. Your doctor should examine your mouth before starting treatment and may advise seeing a dentist. Practice good oral care and consult your doctor or dentist if needed.

Unusual thigh bone fractures. Symptoms include new or unusual pain in your hip, groin, or thigh.

High Blood Calcium After Stopping Treatment. If you have giant cell tumor of bone or are still growing, stopping OSENVELT can lead to high calcium levels in your blood (hypercalcemia). This condition can become severe, require hospitalization, and affect your kidneys. Your doctor will monitor your calcium levels after stopping treatment. Call your doctor right away if you notice symptoms of high blood calcium, such as nausea or vomiting, increased thirst or urination, confusion or tiredness, muscle weakness or pain. Follow your doctor's instructions carefully, and keep all scheduled appointments for calcium monitoring.

Multiple Spine Fractures After Stopping OSENVELT. After stopping treatment with OSENVELT, some patients have experienced multiple spine fractures. Your risk is higher if you have osteoporosis, previous fractures, or other risk factors. Your doctor will assess your individual fracture risk when stopping OSENVELT.

Risk to Unborn Babies. OSENVELT may harm your unborn baby if you take it while pregnant or within 5 months before becoming pregnant. Animal studies have shown serious harm, including pregnancy loss, birth defects, abnormal bone growth, missing lymph nodes, and slow growth after birth. Your doctor will check if you are pregnant before starting OSENVELT. Tell your doctor immediately if you become pregnant or think you may be pregnant during treatment.

Do not take OSENVELT if you have low blood calcium, are pregnant or planning pregnancy, or if you're allergic to denosumab or any ingredients in OSENVELT.

Before taking OSENVELT, tell your doctor if you:

  • take other denosumab products
  • have low blood calcium
  • cannot take daily calcium and vitamin D supplements
  • take medicines that can lower blood calcium
  • plan dental surgery or tooth removal
  • are pregnant, planning pregnancy, or breastfeeding. OSENVELT may harm an unborn baby; a pregnancy test is required before treatment; use effective birth control during treatment and for 5 months after your last dose; inform your doctor immediately if pregnancy occurs. It is unknown if OSENVELT passes into breast milk; do not breastfeed during treatment.

Tell your doctor of all medicines, vitamins, and herbal supplements you take. Keep an updated list to share with healthcare providers.

The most common side effects of OSENVELT are:

For patients with Bone Metastasis from Solid Tumors: fatigue or weakness, low phosphate levels, and nausea.

For patients with Multiple Myeloma: diarrhea, low phosphate, nausea, fatigue, low calcium, shortness of breath, and anemia.

For patients with Giant Cell Tumor of Bone: joint pain, headache, nausea, back pain, fatigue, and pain in arms or legs.

For patients with Hypercalcemia of Malignancy: nausea, trouble breathing, decreased appetite, and headache.

Tell your doctor if side effects are bothersome or persistent. These are not all possible side effects. Call your doctor for advice on side effects or report them to the FDA at 1‑800‑FDA‑1088.

Please see full Prescribing Information and talk with your healthcare provider.

INDICATIONS

OSENVELT (denosumab-bmwo) is a prescription medicine used to:

  • Help prevent bone complications in patients with multiple myeloma and in patients whose cancer from solid tumors has spread to the bones.
  • Treat adults and adolescents (whose bones have stopped growing) with giant cell tumor of bone that cannot be removed with surgery, or when surgery could cause severe complications.
  • Treat high blood calcium caused by cancer (hypercalcemia of malignancy) that has not improved after treatment with bisphosphonates.

Please see full Prescribing Information and talk with your healthcare provider.